Abstract
Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Current Pharmaceutical Design
Title: Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Volume: 16 Issue: 26
Author(s): Kursat Tigen and Cihan Cevik
Affiliation:
Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, beta-blockers, heart failure, metoprolol, carvedilol, bisoprolol, Congestive heart failure, angiotensin-converting enzyme, angiotensin receptor blockers, aldos-terone antagonists, left ventricular, arrhythmias, Catecholamines, cardiomyocytes, renin-angiotensin, apoptosis, myocardial fibers is reduced, the sarcoplasmic reticulum, placebo-controlled, receptors, nebivolol, hemodynamics, bradycardia, Atrial fibrillation, sinus rhythm, Peripheral vascular disease, hypoglycemia, glycosylated hemoglobin, chronic obstructive pulmonary disease, bronchospasm
Abstract: Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.
Export Options
About this article
Cite this article as:
Tigen Kursat and Cevik Cihan, Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?, Current Pharmaceutical Design 2010; 16 (26) . https://dx.doi.org/10.2174/138161210793176473
DOI https://dx.doi.org/10.2174/138161210793176473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Imaging of Myocardial Inflammation: More Evidence Toward a Causative Role in Cardiovascular Disease
Current Radiopharmaceuticals Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?
Current Pharmaceutical Design Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design